FDA Issues New Warning for Copiktra About Increased Risks for Serious Side Effects and Mortality.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 30
- Publication type:
- Article
Works matching IS 21644403 AND DT 2022 AND VI 12 AND IP 9
Results: 17
1
2
Tafinlar plus Mekinist First Tumor-Agnostic Therapy for Any Unresectable or Metastatic Solid Tumors with BRAF Mutation.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 30
- Publication type:
- Article
3
Breyanzi Now FDA Approved for Second-Line Treatment of Large B-Cell Lymphoma.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 29
- Publication type:
- Article
4
Xalkori Now Approved for Treatment of ALK-Positive Inflammatory Myofibroblastic Tumors.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 29
- Publication type:
- Article
5
Nubeqa Receives a New Indication, in Combination with Docetaxel, for Metastatic Hormone-Sensitive Prostate Cancer.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 29
- Publication type:
- Article
6
Enhertu Receives 2 New Indications: HER2 Mutation--Positive NSCLC and HER2-Low Breast Cancer.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 28
- Publication type:
- Article
7
Navigating Global Patients Through H.O.P.E.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 26
- Publication type:
- Article
8
Leveraging Genitourinary Navigation in Urology Groups: Demonstrating the Value of Navigators.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 24
- Publication type:
- Article
9
COVID-19's Impact on Radiation Oncology and Healthcare.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 21
- By:
- Publication type:
- Article
10
Patients Aged ≥55 Years with Luminal A Breast Cancer Can Safely Avoid Radiation.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 18
- By:
- Publication type:
- Article
11
Adding Pembrolizumab to Chemotherapy Prolongs Survival Among Patients with Cervical Cancer Across Several Subgroups.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 16
- By:
- Publication type:
- Article
12
Genmab: Rooted in Science, Driven by Data.
- Published in:
- 2022
- Publication type:
- Interview
13
Adding a Bispecific Antibody to Natural Killer Cells May Be Effective in Relapsed or Refractory CD30-Positive Lymphoma.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 12
- By:
- Publication type:
- Article
14
Neoadjuvant Chemoimmunotherapy Shows Promise in Advanced Ovarian Cancer.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 11
- By:
- Publication type:
- Article
15
Why We Need Correct ICD Coding for Cholangiocarcinoma.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 1
- Publication type:
- Article
16
The Importance of Skills Gap Assessments and Training.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 1
- By:
- Publication type:
- Article
17
"One Size Does Not Fit All" in Newly Diagnosed Multiple Myeloma.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 9, p. 1
- By:
- Publication type:
- Article